Armas debuts generic Vidaza
Armas Pharmaceuticals is launching azacitidine for injection in a 100-mg dosage strength.
Azacitidine for injection is a generic of Pharmion’s Vidaza.
The product is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers.
Azacitidine had a market value of approximately $116 million, the company said.
"We are pleased to launch our first product in the U.S. market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships," Armas president and CEO John Niemi said. "With Armas' strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals."
Azacitidine for injection is a generic of Pharmion’s Vidaza.
The product is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers.
Azacitidine had a market value of approximately $116 million, the company said.
"We are pleased to launch our first product in the U.S. market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships," Armas president and CEO John Niemi said. "With Armas' strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals."